Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells - 15/08/11

Abstract |
Background |
Transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI) expression on B cells is upregulated by Toll-like receptor (TLR) 4.
Objective |
We sought to examine whether TACI synergizes with TLR4 in driving immunoglobulin production by B cells and to examine the mechanism of this synergy.
Methods |
Purified mouse naive B cells were stimulated with the TACI ligand a proliferation-inducing ligand (APRIL) and with suboptimal concentrations of the TLR4 ligand LPS in the presence or absence of IL-4. Immunoglobulin secretion was measured by means of ELISA. Surface IgG1–positive B cells and CD138+ plasmacytoid cells were enumerated by means of FACS. Expression of γ1 and ε germline transcripts, activation-induced cytidine deaminase, and γ1 and ε mature transcripts was measured by means of RT-PCR.
Results |
APRIL synergized with LPS in driving B-cell proliferation and IgM, IgG1, IgG3, IgE, and IgA production. This was mediated by TACI because it was preserved in B-cell maturation antigen−/−, but not TACI−/−, B cells. APRIL and LPS synergized to promote isotype switching, as evidenced by increased expression of activation-induced cytidine deaminase and γ1 and ε mature transcripts and generation of surface IgG1–positive cells. More importantly, APRIL and LPS strongly synergized to drive the plasma cell differentiation program, as evidenced by an increase in CD138+ cells and expression of B lymphocyte induced maturation protein-1 (Blimp-1), interferon regulatory factor-4 (IRF-4), and the spliced form of X-box binding protein-1 (XBP-1). TACI−/− mice had impaired IgM and IgG1 antibody responses to immunization, with a suboptimal dose of the type I T cell–independent antigen 2, 4, 6- Trinitrophenol (TNP)-LPS.
Conclusions |
These observations suggest that TACI cooperates with TLR4 to drive B-cell differentiation and immunoglobulin production in vitro and in vivo.
Le texte complet de cet article est disponible en PDF.Key words : B cells, Toll-like receptor, LPS, transmembrane activator, calcium modulator, and cyclophilin ligand interactor, a proliferation-inducing ligand, immunoglobulin
Abbreviations used : AICDA, APRIL, BAFF, BCMA, Blimp-1, CSR, DC, FITC, GLT, HSPG, IRF-4, NF, PE, sIgG1, TACI, TLR, TNP, WT, XBP-1
Plan
| Supported by March of Dimes grant no. 6-FY07-285 and National Institutes of Health grant AI-031541. |
|
| Disclosure of potential conflict of interest: R. J. Bram is a coinventor of patents, including the TACI gene awarded to St Jude Children’s Hospital. The rest of the authors have concluded that they have no conflict of interest. |
Vol 123 - N° 6
P. 1277 - juin 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
